GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: ...

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...

Alas, this master plan is now in serious doubt. On Nov. 11, the pharmaceutical giant reported that emraclidine failed to meet ...

AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 14th of February ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...

Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...

The current market presents a complex mix of opportunities and risks. Check out my picks that include high-quality, ...

What do you think of when you hear the term ‘patent medicine’? Nostrums, snake oil, or quack medicine, probably. These days, ...

Biden Allows Ukraine to Strike Russia With Long-Range U.S. Missiles President Biden for the first time authorized the use of a system known as ATACMS to help defend Ukraine’s forces in the Kursk ...

The Conservative leader said he will work to bring foreign investment and industry back to Canada with policies similar to Trump's vows to slash taxes and regulations.

Veteran broadcaster Alan Jones has been charged with historical indecent assault and sexual touching offences spanning two decades.